Who does it compete with for the same buyer, and how do they differ?
Against on-site centrifugation PRP, PLT's position rests on a fixed, reportable dose instead of a preparation repeated at every treatment. Each PLT vial delivers one billion platelets and reports the growth factor concentration, and a single blood draw supports multiple treatments, while each centrifugation treatment requires a new blood draw.
PLT can be stored at room temperature for three years. Traditional PRP is non-sterile, cannot be stored, must be used within four hours, and its platelet concentration cannot be measured and may contain other cells. PLT carries no excipient and is prepared in a Class 10,000 laboratory with gamma-ray sterilization.
What could change its growth trajectory, and what would confirm it?
The Japanese build-out is the milestone most likely to change Spirit Scientific Co's growth trajectory, pairing the Tokyo Ariake laboratory completed in December 2024 with a preparation laboratory certified by Japanese PMDA and the PLT-AE preparation service launched in February 2025.
Spirit Scientific Co launched the PLTgel preparation service in August 2024, and in 2023 it expanded its divisions to 100 employees.
What does the product do for its buyer, and how is it delivered?
Spirit Scientific's PLT is a high-concentration platelet therapy made from a patient's own blood, with the PLTgel preparation service launched in August 2024 and the PLT-AE preparation service launched in February 2025.
Spirit Scientific runs preparation from blood collection and patented platelet protection through quantification, lyophilization, growth factor testing, logistics, and gamma-ray sterilization. An app available exclusively to medical institutions tracks preparation progress.